Advances in biotech are redefining the limits of topical beauty. This webinar examines how novel biotech-derived actives and delivery systems are achieving outcomes historically reserved for in-office procedures—without procedural risk, recovery time, or side effects. Join Debut’s founder and CEO, Joshua Britton, and Director of New Business Development, Alexandra Kelley, as we explore the cellular mechanisms, clinical performance, and the breakthrough formulations shaping high performance skincare and color in 2026.
